Cutler Group LP Vir Biotechnology, Inc. Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$19.08 - $26.7 $99,731 - $139,560	-5,227 Reduced 92.73%	410 $10,000
Q4 2021 Jan 18, 2022	SELL	$30.97 - $54.03 $162,933 - $284,251	-5,261 Reduced 48.27%	5,637 $236,000
Q3 2021 Oct 26, 2021	BUY	$34.9 - $54.54 $376,920 - $589,032	10,800 Added 11020.41%	10,898 $474,000
Q2 2021 Jul 19, 2021	BUY	$38.75 - $51.0 $3,565 - $4,692	92 Added 1533.33%	98 $4,000
Q4 2020 Jan 21, 2021	SELL	$25.51 - $43.38 $73,468 - $124,934	-2,880 Reduced 99.79%	6 $0
Q3 2020 Oct 27, 2020	BUY	$28.28 - $53.6 $68,324 - $129,497	2,416 Added 514.04%	2,886 $99,000
Q2 2020 Jul 22, 2020	BUY	$27.89 - $47.86 $13,108 - $22,494	470 New	470 $19,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.